PTC Therapeutics

PTC Therapeutics

PTCT· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock +63.8% in FY2024

Matthew B. Klein is the CEO of PTC Therapeutics and was paid $7.4M in FY2024 (Dec), down 17%.

Pay$100 in the stock at the end of FY21 → $113
CEO pay is from each PTC Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Matthew B. KleinFY2024
  2. 2Eric PauwelsFY2025
  3. 3Neil AlmsteadFY2025
  4. 4Lee GoldenFY2024
  5. 5Pierre GravierFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

PTC Therapeutics paid its 2 named executives $6.7M in total in FY2025 (Dec).

Name
Eric PauwelsChief Business Officer
Neil AlmsteadChief Technical Operations Officer
Matthew B. KleinChief Executive OfficerNot disclosed
Lee GoldenExecutive Vice President and Chief Medical OfficerNot disclosed
Pierre GravierChief Financial OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2024 (Dec) proxy of PTC Therapeutics names 16 peer companies for pay. Among PTC Therapeutics and these peers, CEO pay was the lowest of 9 and total shareholder return was 6th highest of 9.

9th highest of 9in PTC Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:

$7.4M$17.8M

6th highest of 9in PTC Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:

$43$289

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Jerome B. ZeldisDirector · 13 yr on the boardIndependentCompensation, Development, Nominating and Corporate Governance—Paid as an executive
  • Stephanie S. OkeyDirector · 7 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    PTC Therapeutics Chief Technical Operations Officer pay rose 36% to $3.2M. The stock rose 68% in FY2025 (Dec).
    DEF 14A
  2. Pay
    PTC Therapeutics Division head pay rose 49% to $3.6M. The stock rose 68% in FY2025 (Dec).
    DEF 14A
  3. Pay
    PTC Therapeutics CFO pay fell 19% to $2.2M. The stock rose 64% in FY2024 (Dec).
    DEF 14A
  4. Pay
    PTC Therapeutics Chief Technical Operations Officer pay fell 19% to $2.2M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  5. Pay
    PTC Therapeutics CEO pay fell 17% to $7.4M. The stock rose 64% in FY2024 (Dec).
    DEF 14A
  6. Pay
    PTC Therapeutics Division head pay fell 30% to $3.0M. The stock fell 4% in FY2022 (Dec).
    DEF 14A
  7. Pay
    PTC Therapeutics Former CEO pay fell 21% to $5.7M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  8. Pay
    PTC Therapeutics Former CEO pay fell 35% to $7.2M. The stock fell 4% in FY2022 (Dec).
    DEF 14A
  9. Pay
    PTC Therapeutics CEO pay rose 78% to $8.9M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  10. Pay
    PTC Therapeutics General counsel pay fell 18% to $2.2M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  11. Pay
    PTC Therapeutics General counsel pay fell 38% to $2.7M. The stock fell 4% in FY2022 (Dec).
    DEF 14A
  12. Pay
    PTC Therapeutics Division head pay fell 19% to $2.4M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  13. Pay
    PTC Therapeutics Former CFO pay fell 20% to $2.3M. The stock fell 28% in FY2023 (Dec).
    DEF 14A
  14. Pay
    PTC Therapeutics Former CFO pay fell 37% to $2.8M. The stock fell 4% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 20, 2026FY2025
Annual report10-KFeb 19, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data